Synthesis, Characterization and Antitubercular Activity of Novel Chalcone Derivatives by Inha Targeting
Journal of Innovations in Applied Pharmaceutical Science (JIAPS) · 2025
DOI: 10.37022/jiaps.v10i2.705 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Innovations in Applied Pharmaceutical Science (JIAPS), 2025. Verfasst von Santanu Kumar Hotta und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
The authors targeted InhA to estimate the therapeutic potential of novel chalcones against tuberculosis.
Methods
07 synthesized compounds were tested for in vitro antimycobacterial activity against Mycobacterium tuberculosis (H37RV; American Type Culture Collection number: 27294) using the microplate Alamar Blue assay.
Results
The most potent compounds, trans-1-(2-napthyl)-3-phenyl-2-propen-1-one showed in vitro activity, with a minimum inhibitory concentration (MIC) of 1.16 μg/ml.
Conclusion
Compound code 1e i.e. trans-1-(2-napthyl)-3-phenyl-2-propen-1-one showed strong in vitro antimycobacterial activity at a concentration of 1,16 μg/ml.
Zitieren
APA
Hotta, S. K., Prusty, B., Bhuyan, J. R., & Sahu, S. (2025). Synthesis, Characterization and Antitubercular Activity of Novel Chalcone Derivatives by Inha Targeting. Journal of Innovations in Applied Pharmaceutical Science (JIAPS). https://doi.org/10.37022/jiaps.v10i2.705
Vancouver
Hotta SK, Prusty B, Bhuyan JR, Sahu S. Synthesis, Characterization and Antitubercular Activity of Novel Chalcone Derivatives by Inha Targeting. Journal of Innovations in Applied Pharmaceutical Science (JIAPS). 2025. doi:10.37022/jiaps.v10i2.705
BibTeX
@article{Hotta2025,
author = {Hotta, Santanu Kumar and Prusty, Biswanath and Bhuyan, Jochhana Rani and Sahu, Subhrarani},
title = {Synthesis, Characterization and Antitubercular Activity of Novel Chalcone Derivatives by Inha Targeting},
journal = {Journal of Innovations in Applied Pharmaceutical Science (JIAPS)},
year = {2025},
doi = {10.37022/jiaps.v10i2.705}
}
EUVIMED